JP2019510051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510051A5 JP2019510051A5 JP2018551145A JP2018551145A JP2019510051A5 JP 2019510051 A5 JP2019510051 A5 JP 2019510051A5 JP 2018551145 A JP2018551145 A JP 2018551145A JP 2018551145 A JP2018551145 A JP 2018551145A JP 2019510051 A5 JP2019510051 A5 JP 2019510051A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- disorders
- pharmaceutically acceptable
- acceptable salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 68
- 150000003839 salts Chemical class 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 208000035475 disorder Diseases 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical group 0.000 claims description 8
- 229930182558 Sterol Natural products 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 235000003702 sterols Nutrition 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 150000003432 sterols Chemical class 0.000 claims description 5
- 102100036512 7-dehydrocholesterol reductase Human genes 0.000 claims description 4
- 206010072219 Mevalonic aciduria Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000007410 Smith-Lemli-Opitz syndrome Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 206010002091 Anaesthesia Diseases 0.000 claims description 2
- 208000016583 Anus disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000035984 Colonic Polyps Diseases 0.000 claims description 2
- 206010010144 Completed suicide Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 206010064571 Gene mutation Diseases 0.000 claims description 2
- 101000968916 Homo sapiens Methylsterol monooxygenase 1 Proteins 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 102100021091 Methylsterol monooxygenase 1 Human genes 0.000 claims description 2
- 208000026682 Microcephaly-congenital cataract-psoriasiform dermatitis syndrome Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims description 2
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 201000011252 Phenylketonuria Diseases 0.000 claims description 2
- 206010063985 Phytosterolaemia Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 206010039897 Sedation Diseases 0.000 claims description 2
- 208000002227 Sitosterolemia Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 206010048215 Xanthomatosis Diseases 0.000 claims description 2
- 208000012826 adjustment disease Diseases 0.000 claims description 2
- 230000037005 anaesthesia Effects 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000029560 autism spectrum disease Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 208000018459 dissociative disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000036407 pain Effects 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 230000036280 sedation Effects 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 208000029257 vision disease Diseases 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims 1
- 208000016621 Hearing disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000013521 Visual disease Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 description 2
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010051589 Large intestine polyp Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 125000002328 sterol group Chemical group 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021112089A JP7308886B2 (ja) | 2016-04-01 | 2021-07-06 | オキシステロールおよびその使用方法 |
| JP2023110063A JP7693755B2 (ja) | 2016-04-01 | 2023-07-04 | オキシステロールおよびその使用方法 |
| JP2025094185A JP2025131749A (ja) | 2016-04-01 | 2025-06-05 | オキシステロールおよびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317002P | 2016-04-01 | 2016-04-01 | |
| US62/317,002 | 2016-04-01 | ||
| PCT/US2017/025535 WO2017173358A1 (en) | 2016-04-01 | 2017-03-31 | Oxysterols and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112089A Division JP7308886B2 (ja) | 2016-04-01 | 2021-07-06 | オキシステロールおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510051A JP2019510051A (ja) | 2019-04-11 |
| JP2019510051A5 true JP2019510051A5 (enExample) | 2020-05-07 |
| JP7112331B2 JP7112331B2 (ja) | 2022-08-03 |
Family
ID=59965335
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551145A Active JP7112331B2 (ja) | 2016-04-01 | 2017-03-31 | オキシステロールおよびその使用方法 |
| JP2021112089A Active JP7308886B2 (ja) | 2016-04-01 | 2021-07-06 | オキシステロールおよびその使用方法 |
| JP2023110063A Active JP7693755B2 (ja) | 2016-04-01 | 2023-07-04 | オキシステロールおよびその使用方法 |
| JP2025094185A Pending JP2025131749A (ja) | 2016-04-01 | 2025-06-05 | オキシステロールおよびその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112089A Active JP7308886B2 (ja) | 2016-04-01 | 2021-07-06 | オキシステロールおよびその使用方法 |
| JP2023110063A Active JP7693755B2 (ja) | 2016-04-01 | 2023-07-04 | オキシステロールおよびその使用方法 |
| JP2025094185A Pending JP2025131749A (ja) | 2016-04-01 | 2025-06-05 | オキシステロールおよびその使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20190330259A1 (enExample) |
| EP (1) | EP3436022B1 (enExample) |
| JP (4) | JP7112331B2 (enExample) |
| CN (2) | CN114272249A (enExample) |
| AU (3) | AU2017240157B2 (enExample) |
| CA (1) | CA3019146C (enExample) |
| CY (1) | CY1125230T1 (enExample) |
| DK (1) | DK3436022T3 (enExample) |
| ES (1) | ES2921010T3 (enExample) |
| HR (1) | HRP20220716T1 (enExample) |
| HU (1) | HUE059491T2 (enExample) |
| LT (1) | LT3436022T (enExample) |
| MA (1) | MA44526A (enExample) |
| PL (1) | PL3436022T3 (enExample) |
| PT (1) | PT3436022T (enExample) |
| RS (1) | RS63280B1 (enExample) |
| RU (1) | RU2754130C2 (enExample) |
| SI (1) | SI3436022T1 (enExample) |
| SM (1) | SMT202200300T1 (enExample) |
| WO (1) | WO2017173358A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150158903A1 (en) | 2011-09-08 | 2015-06-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| LT2968369T (lt) | 2013-03-13 | 2018-12-27 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai ir jų panaudojimo būdai |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| RS62220B1 (sr) | 2015-07-06 | 2021-09-30 | Sage Therapeutics Inc | Oksisteroli i postupci njihovog korišćenja |
| MX376833B (es) | 2015-07-06 | 2025-03-07 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| CN114272249A (zh) | 2016-04-01 | 2022-04-05 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| AU2017292870B2 (en) | 2016-07-07 | 2021-10-07 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3519422B1 (en) * | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | C7 substituted oxysterols and these compounds for use as nmda modulators |
| ES2952106T3 (es) | 2016-10-18 | 2023-10-27 | Sage Therapeutics Inc | Oxisteroles y procedimientos de utilización de los mismos |
| KR20250054838A (ko) | 2016-10-18 | 2025-04-23 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| WO2022261510A1 (en) | 2021-06-11 | 2022-12-15 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
| JP2024534558A (ja) | 2021-09-22 | 2024-09-20 | セージ セラピューティクス， インコーポレイテッド | 重水素化ｎｍｄａ正調節化合物及びその使用方法 |
| US20250064833A1 (en) | 2021-12-13 | 2025-02-27 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| WO2025020190A1 (zh) * | 2023-07-27 | 2025-01-30 | 珂阑(上海)医药科技有限公司 | 甾类化合物、其制备方法和应用 |
| WO2025021193A1 (zh) * | 2023-07-27 | 2025-01-30 | 珂阑(上海)医药科技有限公司 | 甾类化合物、其制备方法和应用 |
| WO2025021195A1 (zh) * | 2023-07-27 | 2025-01-30 | 珂阑(上海)医药科技有限公司 | 甾类化合物、其制备方法和应用 |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (enExample) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| US4358406A (en) | 1981-07-27 | 1982-11-09 | Wisconsin Alumni Research Foundation | 26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxycholecalciferol and process for preparing same |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| JPH03500049A (ja) | 1987-08-25 | 1991-01-10 | ジー、ケルビン・ダブリュー | ストレス、不安および発作活性の緩和のための組成物および方法 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE4338316A1 (de) | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| NZ282939A (en) | 1994-02-14 | 1998-08-26 | Cocensys Inc | Androstanes and pregnanes for allosteric modulation of gaba receptors |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| WO1996016076A1 (en) | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| KR19990022323A (ko) | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| RU2182909C2 (ru) | 1995-06-23 | 2002-05-27 | Ново Нордиск А/С | Стероиды, способ регулирования мейоза |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| EP0840612A1 (en) | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| WO1999058497A1 (en) | 1998-05-11 | 1999-11-18 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| IL139241A0 (en) | 1998-05-13 | 2001-11-25 | Novo Nordisk As | Meiosis regulating compounds |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| CN1187367C (zh) | 1999-04-29 | 2005-02-02 | 欧洲凯尔特股份有限公司 | 具有麻醉剂活性的3α－羟基－3β－甲氧基甲基－21－杂环取代的类固醇 |
| US6376530B1 (en) | 1999-05-10 | 2002-04-23 | Merck & Co., Inc. | Cyclic amidines useful as NMDA NR2B antagonists |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| DK1392713T3 (da) | 2001-05-03 | 2008-02-18 | Univ Chicago | Lever-X-receptoragonister |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| EP1450816A4 (en) | 2001-11-08 | 2008-02-13 | Univ Chicago | METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE |
| AU2002360489A1 (en) | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
| CN102727501A (zh) | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
| NZ547344A (en) | 2002-03-27 | 2007-11-30 | Phytopharm Plc | Therapeutic methods and uses of sapogenins and their derivatives |
| GB0216621D0 (en) | 2002-07-17 | 2002-08-28 | Imaging Res Solutions Ltd | Imaging compounds |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| CA2506568A1 (en) | 2002-11-22 | 2004-06-10 | Merck & Co., Inc. | 2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists |
| WO2004055201A2 (en) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| US20050142192A1 (en) | 2003-10-15 | 2005-06-30 | Wyeth | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) * | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| AU2005302452B2 (en) | 2004-11-01 | 2010-12-09 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis |
| CA2643732C (en) | 2006-02-27 | 2012-08-21 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| CN101164540A (zh) | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| WO2008057468A1 (en) | 2006-11-02 | 2008-05-15 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| ES2607852T3 (es) | 2006-11-21 | 2017-04-04 | Umecrine Ab | El uso de esteroides de pregnano y androstano para la fabricación de una composición farmacéutica para el tratamiento de trastornos del SNC |
| EP2170828B1 (en) | 2007-06-20 | 2012-11-21 | Auspex Pharmaceuticals, Inc. | Substituted n-aryl pyridinones as fibrotic inhibitors |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| CA2703497A1 (en) | 2007-11-06 | 2009-05-14 | N.V. Organon | A method of hormone suppression in humans |
| CA2707663C (en) | 2007-12-03 | 2017-05-30 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| US8273737B2 (en) | 2008-01-25 | 2012-09-25 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| JP2011520815A (ja) | 2008-05-09 | 2011-07-21 | エモリー・ユニバーシテイ | 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| US8822462B2 (en) | 2009-01-28 | 2014-09-02 | Emory University | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions |
| EP2459581A4 (en) | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X-RECEPTOR AGONISTS |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| GB201008047D0 (en) | 2010-05-14 | 2010-06-30 | Ge Healthcare Ltd | Method of synthesis |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| US20150031655A1 (en) | 2011-04-15 | 2015-01-29 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| EP2714081A4 (en) | 2011-05-27 | 2015-09-09 | Cytocure Llc | METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| US20150158903A1 (en) | 2011-09-08 | 2015-06-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| HUE043171T2 (hu) | 2011-10-07 | 2019-08-28 | Takeda Pharmaceuticals Co | Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek |
| ES2738526T3 (es) * | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| WO2013163455A2 (en) | 2012-04-25 | 2013-10-31 | The Regents Of The University Of California | A drug screening platform for rett syndrome |
| US9737522B2 (en) | 2012-08-09 | 2017-08-22 | Emory University | NMDA receptor modulators and uses related thereto |
| BR112015014397B1 (pt) | 2012-12-18 | 2021-02-02 | Washington University | composto, composição farmacêutica e uso de um composto |
| EP2948152A4 (en) | 2013-01-23 | 2016-12-14 | Sphaera Pharma Private Ltd | NOVEL COMPOUNDS OF 11-BETA HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES RELATED TO MITOCHONDRIA DYSFUNCTION OR ADDITIONAL |
| MX2015009773A (es) | 2013-01-29 | 2016-08-05 | Aptinyx Inc | Moduladores de receptores nmda de espiro-lactama y sus usos. |
| IL286970B2 (en) | 2013-03-13 | 2024-11-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of use thereof |
| LT2968369T (lt) | 2013-03-13 | 2018-12-27 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai ir jų panaudojimo būdai |
| EP3049089B1 (en) | 2013-09-25 | 2019-08-21 | Van Andel Research Institute | Highly potent glucocorticoids |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| EP3204011A4 (en) | 2014-10-07 | 2018-06-20 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| MX376833B (es) | 2015-07-06 | 2025-03-07 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| MA42409A (fr) | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| RS62220B1 (sr) | 2015-07-06 | 2021-09-30 | Sage Therapeutics Inc | Oksisteroli i postupci njihovog korišćenja |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| CN114272249A (zh) * | 2016-04-01 | 2022-04-05 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| AU2017292870B2 (en) | 2016-07-07 | 2021-10-07 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| EP3519422B1 (en) | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | C7 substituted oxysterols and these compounds for use as nmda modulators |
| KR20250054838A (ko) | 2016-10-18 | 2025-04-23 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| ES2952106T3 (es) * | 2016-10-18 | 2023-10-27 | Sage Therapeutics Inc | Oxisteroles y procedimientos de utilización de los mismos |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| CN110945006A (zh) | 2017-06-23 | 2020-03-31 | 英特塞普特医药品公司 | 用于制备胆汁酸衍生物的方法和中间体 |
| SG10202110563YA (en) | 2017-11-10 | 2021-11-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| US20250064833A1 (en) | 2021-12-13 | 2025-02-27 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| AU2022409329A1 (en) | 2021-12-13 | 2024-07-11 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of huntington's disease |
-
2017
- 2017-03-31 CN CN202111482711.3A patent/CN114272249A/zh active Pending
- 2017-03-31 MA MA044526A patent/MA44526A/fr unknown
- 2017-03-31 SM SM20220300T patent/SMT202200300T1/it unknown
- 2017-03-31 RU RU2018138183A patent/RU2754130C2/ru active
- 2017-03-31 ES ES17776839T patent/ES2921010T3/es active Active
- 2017-03-31 CN CN201780032798.XA patent/CN109195604B/zh active Active
- 2017-03-31 PL PL17776839.7T patent/PL3436022T3/pl unknown
- 2017-03-31 WO PCT/US2017/025535 patent/WO2017173358A1/en not_active Ceased
- 2017-03-31 EP EP17776839.7A patent/EP3436022B1/en active Active
- 2017-03-31 DK DK17776839.7T patent/DK3436022T3/da active
- 2017-03-31 PT PT177768397T patent/PT3436022T/pt unknown
- 2017-03-31 LT LTEPPCT/US2017/025535T patent/LT3436022T/lt unknown
- 2017-03-31 CA CA3019146A patent/CA3019146C/en active Active
- 2017-03-31 HU HUE17776839A patent/HUE059491T2/hu unknown
- 2017-03-31 RS RS20220536A patent/RS63280B1/sr unknown
- 2017-03-31 SI SI201731174T patent/SI3436022T1/sl unknown
- 2017-03-31 AU AU2017240157A patent/AU2017240157B2/en active Active
- 2017-03-31 JP JP2018551145A patent/JP7112331B2/ja active Active
- 2017-03-31 US US16/089,896 patent/US20190330259A1/en not_active Abandoned
- 2017-03-31 HR HRP20220716TT patent/HRP20220716T1/hr unknown
-
2021
- 2021-04-28 US US17/242,860 patent/US11884697B2/en active Active
- 2021-07-06 JP JP2021112089A patent/JP7308886B2/ja active Active
-
2022
- 2022-06-09 CY CY20221100401T patent/CY1125230T1/el unknown
- 2022-12-19 AU AU2022291419A patent/AU2022291419B2/en active Active
-
2023
- 2023-07-04 JP JP2023110063A patent/JP7693755B2/ja active Active
- 2023-12-11 US US18/535,256 patent/US12448409B2/en active Active
-
2024
- 2024-12-04 AU AU2024278111A patent/AU2024278111A1/en active Pending
-
2025
- 2025-06-05 JP JP2025094185A patent/JP2025131749A/ja active Pending